Release Details

CRESTWOOD, Ky. and CAMBRIDGE, Mass., Feb. 23, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, today announced that the Company plans to participate in two upcoming investor conferences.

• Apellis’ management will participate in the BTIG 2018 Healthcare Conference being held February 26, 2018 to March 2, 2018 in Snowbird, UT. There will be no formal presentation or webcast, due to the format of this event.
   
• Apellis CEO and co-founder Cedric Francois, MD, PhD, will provide a company overview at the Cowen and Company 38^th Annual Health Care Conference on Monday, March 12, 2018 at 4:10 p.m. ET in Boston, MA.

The Cowen presentation will be available via live webcast from the “Events and Presentations” page of the “Investors and Media” section of the Company’s website at http://www.apellis.com. A replay of the webcast will be available for 90 days following the event.

About Apellis
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds for the treatment of a broad range of life-threatening or debilitating autoimmune diseases based upon complement immunotherapy through the inhibition of the complement system at the level of C3. Apellis is the first company to advance chronic therapy with a C3 inhibitor into clinical trials. For additional information about Apellis and APL-2, please visit http://www.apellis.com.

Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the implications of preliminary clinical data. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether preliminary or interim results from a clinical trial will be predictive of the final results of the trial; whether results obtained in preclinical studies and clinical trials such as the results referenced in this release will be indicative of results that will be generated in future clinical trials; whether APL-2 will successfully advance through the clinical trial process on a timely basis, or at all, and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if Apellis’ products receive approval, they will be successfully distributed and marketed; and other factors discussed in the “Risk Factors” section of Apellis’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on December 20, 2017, and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contact:
Luke Heaglelheagle@w2ogroup.com
910.726.1372  (office)
910.619.5764  (mobile)

Media Contact:
Tully Nicholas
tnicholas@denterlein.com
617.482.0042 (office)
860.490.0218 (mobile)

Source: Apellis Pharmaceuticals, Inc.